The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of EUR 0.22 per share (previous year: EUR 0.17) for the 2025 fiscal year. As in previous years, the Annual General Meeting was held as an in-person event, right next to the Eckert & Ziegler SE headquarters in Berlin. In total, 55.37 % of the company’s share capital was represented. The Annual General Meeting endorsed the members of the Executive Board and the Supervisory Board of Eckert & Ziegler SE for the 2025 fiscal year and approved all items on the agenda by a large majority.
The dividend increase to EUR 0.22 per share represents a significant 29.4% rise from the previous year's EUR 0.17, signaling confidence in the company's financial health and future prospects. This decision underscores the company's commitment to returning value to shareholders while maintaining a balanced approach to capital allocation. The high level of representation at the meeting, with over half of the share capital present, indicates strong shareholder engagement and support for the company's strategic direction.
The detailed voting results of the Annual General Meeting and the CEO’s presentation are available on the Eckert & Ziegler SE website: https://www.ezag.com/investors/annual-general-meeting/.
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
The approval of the higher dividend comes at a time when the company continues to play a critical role in the medical isotope sector, particularly in the development and supply of components for cancer diagnosis and treatment. As the demand for nuclear medicine and radiation therapy grows, Eckert & Ziegler's expertise in isotope-related technologies positions it well for sustained growth. The dividend increase not only rewards shareholders but also reflects the company's robust cash flow generation and confidence in its long-term business outlook.
